News

BASF wants Pronova
Enlarge image

BusinessNorwayGermany

BASF wants Pronova

22.11.2012 - BASF plans to expand its leading position in the market for omega-3 fatty acids with an takeover of Norwegian Pronova Biopharma.

On November 21, the world’s largest chemical company in the world announced it has reached an agreement with Pronova BioPharma ASA’s Board of Directors to make a recommended voluntary public takeover offer. Under the terms of the agreement,  BASF is to pay NOK 12.50 (€1,70) in cash for each Pronova share, valuating the Lysaker-based specialist at NOK4.8bn (€664m).

With the acquisition of Pronova, BASF would immediately achieve a leading position in the growing market for omega-3 fatty acids.  BASF said it has already obtained irrevocable pre-acceptance commitments for approximately 60% of Pronova’s share capital; including the 50.0% stake held by majority shareholders Herkules Private Equity Fund, an approximate 9.1% stake, indirectly controlled by investment firms Kistefos AS and Kistefos Investment AS, with 0.3% held by members of the Board of Directors and management of Pronova.

The offer corresponds to a premium of 24% above the volume-weighted average share price for Pronova’s shares in the six months prior to announcement of the public takeover offer. 

“The intended acquisition will significantly strengthen our position in the fast growing and highly profitable market for omega-3 fatty acids. We want to combine the global market reach and experience of BASF with the know-how of Pronova in omega-3 fatty acids,” said Michael Heinz, Member of the Board of Executive Directors of BASF SE and responsible for the Performance Products segment, which includes the Nutrition & Health division. 

Pronova’s active pharmaceutical ingredients are used to treat cardiovascular diseases such as post-myocardial infarction. In nutritional applications, including dietary supplements, there is a strong body of evidence supporting a broad range of positive health benefits through omega-3 fatty acids, for example, in the areas of cognitive development or heart health. 

© eurobiotechnews.eu/tg

http://www.european-biotechnology-news.com/news/news/2012-04/basf-wants-pronova.html

BusinessUK

20.08.2014 Biopharmaceutical contract manufacturer Fujifilm Diosynth Biotechnologies is expanding its cell culture manufacturing capacity further with a new 2,000l single-use bioreactor at the company’s site in Billingham, UK.

BusinessEUGermanyUK

15.08.2014 Some of Europe’s biggest pharma companies are competing in a bidding war for US biotech Intermune Inc., Bloomberg reports, citing insider reports as the source.

ResearchEUGermanyUK

13.08.2014 The Ebola epidemic is still raging on in West Africa and thus far there is

neither vaccine nor cure for the viral disease. The only flickers of hope:

an experimental antibody serum and an early-stage vaccine.

BusinessFrance

11.08.2014 Will Sanofi succeed where Pfizer failed? The French pharmaceutical company has taken on the commercialisation of Mannkind Corporation’s inhaled insulin product Afrezza.

ResearchSwedenGermany

08.08.2014 Boehringer Ingelheim is walking away from Swedish Orexo's prostaglandin inhibition project OX-MPI. Germany's largest researching pharmaceutical company had been responsible for the project's research and development since 2005.

ResearchSwitzerlandDenmark

06.08.2014 Roche is re-expanding its involvement in RNAi technologies. The Swiss pharmaceutical company will pay up to €335m for the acquisition of the Danish company Santaris Pharma A/S.

ResearchUKSwitzerland

03.08.2014 In its efforts to become the leading country in genetic research, the UK has attracted investments worth more than £300m (€376m) to map 100,000 human genomes by 2017.

BusinessSpainUKSweden

31.07.2014 Astrazeneca is buying the rights to Almirall’s respiratory drugs in a deal worth up to €1.56bn.

BusinessFranceGermanySwitzerlandUK

30.07.2014 Rumours have it that French Danone wants to sell its medical nutrition business to US drugmaker Hospira for US$5bn in yet another tax inversion deal.

Events

All Events

Current issue

All issues

Product of the week

Products

Stock list

All quotes

TOP

  • 4SC1.23 EUR0.00%
  • ACTELION108.80 CHF0.00%
  • ADDEX4.00 CHF0.00%

FLOP

  • CYTOTOOLS31.45 EUR-0.47%
  • 4SC1.23 EUR0.00%
  • ACTELION108.80 CHF0.00%

TOP

  • SANTHERA82.95 CHF20.4%
  • LONZA101.10 CHF6.1%
  • MAGFORCE6.50 EUR5.7%

FLOP

  • WILEX2.36 EUR-25.1%
  • MOLOGEN7.10 EUR-24.5%
  • VITA 343.96 EUR-18.4%

TOP

  • SANTHERA82.95 CHF3758.1%
  • CO.DON2.50 EUR228.9%
  • PAION2.48 EUR195.2%

FLOP

  • CYTOS0.26 CHF-93.6%
  • MEDIGENE4.65 EUR-68.1%
  • MERCK KGAA64.40 EUR-45.7%

No liability assumed, Date: 22.08.2014